Moreover, in vivo studies demonstrated that DNAJC13-deficient tumors were more sensitive to anti-CD47 antibody therapy, resulting in reduced tumor growth and increased immune activation, as reflected by decreased Ki-67 and elevated cleaved caspase-3 staining. This evidence concerns the gene CASP3 and neoplasm.